Axon Enterprise, Inc. (NASDAQ:AXON) Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 4.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,657 shares of the biotechnology company’s stock after acquiring an additional 617 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Axon Enterprise were worth $4,602,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. 9258 Wealth Management LLC acquired a new stake in Axon Enterprise in the fourth quarter valued at approximately $204,000. Beacon Pointe Advisors LLC purchased a new stake in Axon Enterprise in the 4th quarter worth $218,000. Robeco Institutional Asset Management B.V. raised its position in Axon Enterprise by 1,049.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 59,319 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 54,160 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Axon Enterprise by 11.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,320 shares of the biotechnology company’s stock valued at $1,116,000 after purchasing an additional 427 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Axon Enterprise by 8.0% in the fourth quarter. Assetmark Inc. now owns 4,438 shares of the biotechnology company’s stock valued at $1,146,000 after purchasing an additional 329 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In other news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the sale, the director now owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Julie A. Cullivan sold 900 shares of Axon Enterprise stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now directly owns 3,653 shares in the company, valued at $1,291,445.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the transaction, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 317,981 shares of company stock worth $115,662,734. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $393.29 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The business’s fifty day moving average price is $348.04 and its two-hundred day moving average price is $317.24. The stock has a market cap of $29.68 billion, a PE ratio of 115.00, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94. Axon Enterprise, Inc. has a one year low of $189.12 and a one year high of $393.58.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the previous year, the company earned $0.80 EPS. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. On average, analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on AXON. Craig Hallum lifted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target for the company. JMP Securities increased their price objective on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Barclays lifted their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Robert W. Baird increased their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.